BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38278927)

  • 21. Analysis of genetic variants of frequently mutated genes in human papillomavirus-negative primary head and neck squamous cell carcinoma, resection margins, local recurrences and corresponding circulating cell-free DNA.
    Flach S; Kumbrink J; Walz C; Hess J; Drexler G; Belka C; Canis M; Jung A; Baumeister P
    J Oral Pathol Med; 2022 Sep; 51(8):738-746. PubMed ID: 35895622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.
    Shen N; Zhang D; Yin L; Qiu Y; Liu J; Yu W; Fu X; Zhu B; Xu X; Duan A; Chen Z; Wang X; Cao X; Zhao T; Zhou Z; Yu L; Qin H; Fang Z; Li JY; Liu Y; Xiong L; Yuan B; Li F; Zhang Y
    Oncol Rep; 2019 Aug; 42(2):549-560. PubMed ID: 31173267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. cfDNA methylation in liquid biopsies as potential testicular seminoma biomarker.
    Raos D; Oršolić D; Mašić S; Tomić M; Krasić J; Tomašković I; Gabaj NN; Gelo N; Kaštelan Ž; Kuliš T; Bojanac AK; Barešić A; Ulamec M; Ježek D; Sincic N
    Epigenomics; 2022 Dec; 14(23):1493-1507. PubMed ID: 36722130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting tumour content of liquid biopsies from cell-free DNA.
    Cardner M; Marass F; Gedvilaite E; Yang JL; Tsui DWY; Beerenwinkel N
    BMC Bioinformatics; 2023 Sep; 24(1):368. PubMed ID: 37777714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.
    Del Re M; Crucitta S; Paolieri F; Cucchiara F; Verzoni E; Bloise F; Ciampi R; Mercinelli C; Capuano A; Sportiello L; Martinetti A; Procopio G; Galli L; Porta C; Bracarda S; Danesi R
    J Transl Med; 2022 Aug; 20(1):371. PubMed ID: 35974365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis.
    Moldovan N; van der Pol Y; van den Ende T; Boers D; Verkuijlen S; Creemers A; Ramaker J; Vu T; Bootsma S; Lenos KJ; Vermeulen L; Fransen MF; Pegtel M; Bahce I; van Laarhoven H; Mouliere F
    Cell Rep Med; 2024 Jan; 5(1):101349. PubMed ID: 38128532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salivary microRNA miR-let-7a-5p and miR-3928 could be used as potential diagnostic bio-markers for head and neck squamous cell carcinoma.
    Fadhil RS; Wei MQ; Nikolarakos D; Good D; Nair RG
    PLoS One; 2020; 15(3):e0221779. PubMed ID: 32208417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and monitoring of virus-associated cancer using cell-free DNA.
    Scholte LL; Bethony JM; Xian RR
    Curr Opin Virol; 2023 Jun; 60():101331. PubMed ID: 37187125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of HTLV-1 proviral DNA in cell-free DNA: Potential for non-invasive monitoring of Adult T cell leukaemia/lymphoma using liquid biopsy?
    Joris T; Haddow J; Taylor GP; Cook LBM; Rowan AG
    Front Immunol; 2023; 14():1150285. PubMed ID: 37114063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid biopsy with cell free DNA: new horizons for prostate cancer.
    Ponti G; Maccaferri M; Percesepe A; Tomasi A; Ozben T
    Crit Rev Clin Lab Sci; 2021 Jan; 58(1):60-76. PubMed ID: 32805148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
    Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
    Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma.
    Kumari S; Husain N; Agarwal A; Neyaz A; Gupta S; Chaturvedi A; Lohani M; Sonkar AA
    Pathol Oncol Res; 2019 Jul; 25(3):925-936. PubMed ID: 29376201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
    Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
    Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy.
    Zwirner K; Hilke FJ; Demidov G; Ossowski S; Gani C; Rieß O; Zips D; Welz S; Schroeder C
    Radiother Oncol; 2018 Dec; 129(3):575-581. PubMed ID: 30097252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients.
    Dietrich D; Weider S; de Vos L; Vogt TJ; Färber M; Zarbl R; Hunecke A; Glosch AK; Gabrielpillai J; Bootz F; Bauernfeind FG; Kramer FJ; Kristiansen G; Brossart P; Strieth S; Franzen A
    Clin Chem; 2023 Sep; 69(9):1050-1061. PubMed ID: 37477541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell-Free Human Papillomavirus-DNA for Monitoring Treatment Response of Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
    Campo F; Zocchi J; Moretto S; Mazzola F; Petruzzi G; Donà MG; Benevolo M; Iocca O; De Virgilio A; Pichi B; Manciocco V; Pellini R
    Laryngoscope; 2022 Mar; 132(3):560-568. PubMed ID: 34236084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
    Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
    Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
    Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
    Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs).
    Economopoulou P; Kotsantis I; Kyrodimos E; Lianidou ES; Psyrri A
    Oral Oncol; 2017 Nov; 74():83-89. PubMed ID: 29103757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
    Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
    Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.